Metformin induced acute pancreatitis and lactic acidosis in a patient on hemodialysis.
10.12701/yujm.2016.33.1.33
- Author:
Yeon Kyung LEE
1
;
Kihyun LIM
;
Su Hyun HWANG
;
Young Hwan AHN
;
Gyu Tae SHIN
;
Heungsoo KIM
;
In Whee PARK
Author Information
1. Department of Nephrology, Ajou University School of Medicine, Suwon, Korea. inwhee@empal.com
- Publication Type:Case Report
- Keywords:
Metformin;
Pancreatitis;
Lactic acidosis;
Diabetes mellitus
- MeSH:
Acidosis;
Acidosis, Lactic*;
Amylases;
Diabetes Mellitus;
Diabetic Nephropathies;
Female;
Humans;
Hypertension;
Insulin;
Lactic Acid;
Lipase;
Metformin*;
Middle Aged;
Nausea;
Pancreatitis*;
Renal Dialysis*;
Sitagliptin Phosphate;
Vomiting
- From:Yeungnam University Journal of Medicine
2016;33(1):33-36
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Metformin, commonly prescribed for type 2 diabetes, is considered safe with minimal side-effect. Acute pancreatitis is rare but potentially fatal adverse side-effect of metformin. We report a patient on hemodialysis with metformin-related acute pancreatitis and lactic acidosis. A 62-year-old woman with diabetic nephropathy and hypertension presented with nausea and vomiting for a few weeks, followed by epigastric pain. At home, the therapy of 500 mg/day metformin and 50 mg/day sitagliptin was continued, despite symptoms. Laboratory investigations showed metabolic acidosis with high levels of lactate, amylase at 520 U/L (range, 30-110 U/L), and lipase at 1,250 U/L (range, 23-300 U/L). Acute pancreatitis was confirmed by computed tomography. No recognized cause of acute pancreatitis was identified. Metformin was discontinued. Treatment with insulin and intravenous fluids resulted in normalized amylase, lipase, and lactate. When she was re-exposed to sitagliptin, no symptoms were reported.
